Background: Early revascularisation of the culprit lesion is the therapeutic cornerstone in cardiogenic shock complicating acute myocardial infarction. The optimal management of additional non-culprit lesions is unclear. This systematic review and meta-analysis aims to summarise current evidence on the comparison of immediate multivessel percutaneous coronary intervention (MV-PCI) or culprit lesion only PCI with possible staged revascularisation (C-PCI) in patients with cardiogenic shock complicating acute myocardial infarction. Methods: Medical literature databases were screened to identify analyses comparing MV-PCI with C-PCI in patients with cardiogenic shock complicating acute myocardial infarction and multivessel coronary artery disease. In absence of randomised trials, 10 cohort studies were included in the current meta-analysis. The primary outcome of short-term mortality was assessed at hospital discharge or 30 days after hospital admission. Secondary outcomes were long-term mortality as well as myocardial re-infarction, stroke, acute renal failure, and bleeding at short-term follow-up. Results: Of 6051 patients, 1194 (19.7%) received MV-PCI and 4857 (80.3%) C-PCI. Short-term mortality was 37.5% in patients undergoing MV-PCI compared with 28.8% in C-PCI patients (risk ratio 1.26, 95% confidence interval 1.12-1.41, p=0.001). Long-term mortality (p=0.77), myocardial re-infarction (p=0.77), stroke (p=0.12), acute renal failure (p=0.17) and bleeding (p=0.53) did not differ significantly between the two revascularisation groups. Conclusions: Results of this first meta-analysis on the interventional management of patients with cardiogenic shock complicating acute myocardial infarction and multivessel coronary artery disease do not support MV-PCI over C-PCI. However, possible treatment selection bias in the individual studies must be taken into account.
Introduction
The majority of patients with cardiogenic shock complicating acute myocardial infarction (AMI) display multivessel coronary artery disease (MVD) with significant stenoses in addition to the culprit lesion. 1 While early revascularisation of the culprit lesion preferably performed by percutaneous coronary intervention (PCI) is the therapeutic cornerstone, the optimal management of additional non-culprit lesions is unclear. 2 Two possible approaches are debated: 1) an aggressive strategy with acute ad hoc multivessel PCI (MV-PCI) of all angiographically significant stenoses, and 2) a more conservative approach with PCI of the culprit lesion only in the acute setting and possible staged PCI of other remaining significant lesions (C-PCI). Reports from non-randomised studies comparing MV-PCI with C-PCI have shown inconsistent results and thus evidence supporting one strategy over the other is scarce. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] This evidence gap is also reflected by either lacking or inconsistent guideline recommendations. [13] [14] [15] [16] [17] [18] Therefore, aim of this systematic review and metaanalysis is to summarise current evidence focusing on the comparison of MV-PCI with C-PCI in patients with cardiogenic shock complicating AMI.
Methods
Based on PRISMA guidelines, two investigators (SdW and HT) searched medical literature databases of Pubmed/ Medline and the Cochrane Central Register of Controlled Trials (CENTRAL) using three search term groups of which at least one term of each group was required to match: 1) acute coronary syndrome, acute myocardial infarction, ST-elevation myocardial infarction, STEMI, non-ST-elevation acute coronary syndrome, non-ST-elevation myocardial infarction, NSTEMI; 2) cardiogenic shock, shock, haemodynamic/hemodynamic instability; 3) multivessel coronary artery disease, multivessel disease, multivessel percutaneous coronary intervention, culprit only. Reference lists from review articles and eligible studies were further checked to identify additional citations. Studies eligible for inclusion compared MV-PCI with C-PCI in patients with cardiogenic shock complicating AMI reperfused by primary PCI and reported at least allcause mortality. No restrictions on publication date and language were applied.
Data acquisition and outcome measures
Patient and outcome data were independently extracted by two investigators (SdW and AJ). Seven studies reported the absolute number of events or percentage of patients in whom an event occurred. 3, 4, [8] [9] [10] [11] [12] Three studies reported Kaplan-Meier estimates. [5] [6] [7] The primary outcome of this meta-analysis was all-cause mortality at short-term follow-up. Secondary efficacy endpoints included all-cause mortality at long-term follow-up as well as myocardial reinfarction at short-term follow-up. Secondary safety outcomes were stroke, acute renal failure, and bleeding at short-term follow-up.
Short-term follow-up was defined as the time period until hospital discharge or 30 days following the index hospitalisation. Long-term follow-up was defined as the time period ≥6 months after the index hospitalisation. Clinical events were analysed according to study-specific definitions.
Statistical analysis
Baseline characteristics containing demographics, medical history, haemodynamic parameters and angiographic parameters were tabulated by treatment group for each study. Continuous variables were summarised as mean and standard deviation, or median and interquartile range as initially reported for each study. Frequencies and percentages were used to summarise categorical variables. Random effects meta-analyses were performed by calculating risk ratios (RR) with 95% confidence intervals (95% CI) for MV-PCI versus C-PCI of each individual study and consecutive pooling by means of the MantelHaenszel method. 19 Between-study variance τ 2 was calculated according DerSimonian and Laird. 20 Cochran's Q statistic and Higgins and Thompson's I 2 were calculated to assess heterogeneity. 21 p-values <0.05 and <0.10 were considered statistically significant for clinical outcomes and heterogeneity, respectively. Clinical outcome measures were presented by means of forest plots. All analyses were performed by using R version 3.1.0 (The R Project for Statistical Computing, Vienna, Austria) and its meta package version 4.7-0 (cran.r-project.org/web/packages/ meta/).
Results

Characteristics of the included studies
In the absence of randomised trials, 10 observational studies published between 2003 and 2016 were identified and included in the meta-analysis (Figure 1 ). Characteristics of each study are depicted in Table 1 and outcome definitions of the individual studies are listed in Table 2 ." All but three studies were multicentre analyses. The definition of MVD was comparable in the cohorts and seven studies focused exclusively on ST-elevation myocardial infarction (STEMI). A total of 6051 patients were included with 1194 (19.7%) receiving MV-PCI and 4857 (80.3%) undergoing C-PCI. Overall, baseline characteristics of individual studies did not show major inhomogeneities (Table 3) .
Efficacy
Short-term mortality was assessed in 5656 patients enrolled in seven studies. Short-term mortality was significantly higher in patients reperfused by MV-PCI in comparison with those undergoing C-PCI (37.5% versus 28.8%; RR 1.26, 95% CI 1.12-1.41, p=0.001; Figure 2(a) ). Long-term mortality was reported in seven studies consisting of 1893 patients and was 44.7% in patients treated by MV-PCI versus 41.7% in those undergoing C-PCI (RR 1.03, 95% CI 0.85-1.25, p=0.77; Figure 2(b) ). Data on myocardial reinfarction at short-term follow-up were reported in four studies (Figure 2(c) ). The incidence of myocardial reinfarction was low (1.7% versus 2.0%) without significant differences between groups (RR 0.87, 95% CI 0.35-2.16, p=0.77).
Safety
Overall, 63 strokes in 4525 patients enrolled in five studies were recorded (1.4%, Figure 3 (a)). The rate of stroke trended to be higher in patients undergoing MV-PCI in comparison with those treated by C-PCI (1.8% versus 1.3%; RR 1.59, 95% CI 0.88-2.88, p=0.12). Similarly, acute renal failure occurring in 353 of 4922 patients (7.2%) enrolled in five studies was numerically more frequent in patients reperfused by MV-PCI (8.9% versus 6.8%; RR 1.26, 95% CI 0.90-1.76, p=0.17; Figure 3 (b)). Finally, bleeding was assessed in six studies and 5260 patients. The rate of bleeding did not significantly differ between both groups (7.5% versus 8.7%; RR 1.08, 95% CI 0.85-1.37, p=0.53; Figure 3 
Discussion
This first meta-analysis from 10 cohort studies investigating the efficacy and safety of MV-PCI versus C-PCI in patients with MVD and cardiogenic shock complicating AMI demonstrates an increased short-term mortality following MV-PCI in comparison with C-PCI. Conversely, no differences with respect to mortality at long-term follow-up could be observed. The incidence of myocardial re-infarction was infrequent independent of the revascularisation strategy. Neither strategy was superior in terms of stroke, acute renal failure, and bleeding.
MVD is present in the vast majority of patients with cardiogenic shock complicating AMI and is associated with higher mortality rates as compared with patients with single vessel disease. 22 While PCI of the culprit lesion is established standard practice, the optimal management of additional non-culprit lesions is the subject of intense debate. Potential advantages of MV-PCI include an enhanced perfusion of the peri-infarct area, which may positively impact on left ventricular function and potentially reduce infarct size. Further, MV-PCI could prevent early and late recurrent ischaemia in non-infarct related lesions. On the other hand, PCI of additional lesions may induce a second-hit due to distal embolisation, loss of side branch or acute vessel occlusion with subsequent haemodynamic deterioration. Moreover, MV-PCI increases the risks of prolonged interventional procedures with the need for higher amounts of contrast dye and a subsequent increased risk of contrastinduced renal failure translating into increased morbidity and mortality. High amounts of contrast dye can also lead to acute volume overload of the left ventricle with subsequent negative impact on myocardial recovery. Finally, angiographic significance of lesions does not necessarily reflect flow limitation and coronary spasm may lead to overestimation of lesion severity, which might lead to unnecessary procedures without a clinical benefit and only additional risk.
The main finding of this meta-analysis is the excess short-term mortality in patients treated by MV-PCI in comparison with those undergoing C-PCI. This result merits careful discussion as this analysis of non-randomised trials without individual patient data is prone to treatment selection bias. On the one hand, the likelihood to perform MV-PCI could be higher in patients with more severe MVD Yang et al. 6 Cavender et al. 7 MV-PCI as well as pronounced haemodynamic instability, which could translate into the observed excess mortality independent of an effect of MV-PCI itself. On the other hand, factors triggering the decision in favour of an aggressive treatment strategy such as MV-PCI may be younger age, a lower prevalence of co-morbidities as well as less complex MVD with a subsequent angiographic success rate expected to be high. Baseline variables of the individual studies according to treatment strategy could give further insight. Age, prevalence of cardiovascular risk factors as well as haemodynamic parameters or left ventricular ejection fraction were, however, equally distributed between patients undergoing MV-PCI versus those treated by C-PCI in the majority of the studies. As individual data were not available for the present meta-analysis, we could not perform adjusted analyses. Six of the individual studies undertook adjusted analyses with conflicting results. Only one study demonstrated an association of MV-PCI with improved survival at short-term follow-up after adjustment for baseline characteristics. 5 Contrarily, two studies observed an association of MV-PCI with short-term mortality adjusted for detailed sets of clinical and functional parameters. 4, 11 Additional three studies performed multivariable analyses and did find MV-PCI to be neither protective nor predictive for short-term mortality. 6, 7, 10 The current analysis cannot distinguish between truly detrimental effects of MV-PCI and the influence of bias and confounding inherent in cohort studies. Therefore, the results of this analysis must be interpreted with caution. Nevertheless, taking into account the results of similar long-term mortality and comparable rates of myocardial re-infarction and bleeding, as well as strong trends for higher rates of stroke and acute renal failure, a beneficial effect of MV-PCI appears unlikely.
International guidelines are conflicting with respect to the recommended revascularisation strategy in patients with cardiogenic shock complicating AMI and MVD. Current European guidelines recommend that PCI of additional lesions should be limited to the presence of multiple truly critical (≥90% diameter) stenoses or highly unstable lesions with angiographic signs of possible thrombus or lesion disruption, and if there is persistent ischaemia after PCI of the supposed culprit lesion in patients with STEMI. 13, 14 American guidelines on the management of patients with STEMI state that PCI of a severe stenosis in a large non-infarct artery might improve haemodynamic stability and should therefore be considered during the primary procedure. 15 Notably, neither European nor American non-ST-elevation myocardial infarction (NSTEMI) guidelines give recommendations, despite the fact that a relevant portion of cardiogenic shock patients present with NSTEMI. 16, 17, 23, 24 In contrast, American appropriate use criteria for coronary revascularisation consider immediate revascularisation of one or more coronary arteries to be appropriate, both in STEMI and in NSTEMI. 18 Combining the findings of the individual studies as well as the current meta-analysis, one may conclude that there is insufficient evidence endorsing a recommendation for MV-PCI in patients with cardiogenic shock complicating AMI. So far, the recommendation for MV-PCI can be based on expert opinion only. Prospective randomised adequately powered clinical trials such as the ongoing CUPLRIT-SHOCK study randomising multivessel AMI-related cardiogenic shock patients to C-PCI with possible staged non-culprit lesion revascularisation versus immediate MV-PCI will provide further evidence (ClinicalTrials.gov Identifier: NCT01927549). 25 Apart from the possible treatment selection bias in the individual studies, additional limitations of this study should be acknowledged. First, the definitions of myocardial re-infarction, stroke, acute renal failure, and bleeding varied among the individual studies. Furthermore, in-hospital and 30-day mortality data were combined to shortterm mortality due to different endpoint definitions. Second, only a minority of the included trials adjudicated clinical events by an independent clinical events committee. Third, secondary outcomes such as myocardial re-infarction, stroke, acute renal failure, and bleeding were reported in only approximately half of all studies. Further, data on additional PCI performed as staged procedures were not consistently reported and could therefore not be analysed. In contrast to data on the primary outcome of shortterm mortality as well as secondary outcomes including myocardial re-infarction, stroke, acute renal failure, and bleeding, results with respect to long-term mortality display significant heterogeneity (I 2 =67.8%, p=0.005). This should be taken into account when interpreting the data. Moreover, a sub-analysis of NSTEMI patients would be of interest, which could not be performed due to the lack of individual data. However, only a small number of patients presented with NSTEMI (n=338) and consequently the validity of the results would be questionable due to the limited statistical power. Finally, both Kaplan-Meier and the absolute number of events or percentage of patients in whom an event occurred were used to calculate RR.
Conclusions
Results of this first meta-analysis on the interventional management of patients with cardiogenic shock complicating AMI and MVD do not support MV-PCI over C-PCI. However, possible treatment selection bias in the individual studies must be taken into account. A prospective randomised adequately powered clinical trial is warranted.
